Drugs / ladiratuzumab vedotin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01969643 | Oct 2013 → Feb 2023 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03310957 | Feb 2018 → Sep 2024 | triple-negative breast carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04032704 | Oct 2019 → Nov 2023 | esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma +4 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06362590 Background | — | — | Seagen Inc. | Available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ladiratuzumab vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06362590 ↗ |
| Known as | Ladiratuzumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298101 ↗ |
| Known as | Ladiratuzumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298101 ↗ |
| Known as | SGN-LIV1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03424005 ↗ |
| Route | Intravenous | “SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10” NCT01042379 ↗ |
| Target | SLC39A6 | “Zinc transporter ZIP6 binding agent” CHEMBL4298101 ↗ |